Proinnovera
Proinnovera is a German-based Global CRO providing clinical research and topical formulation development services to pharmaceutical and biotech clients across dermatology, aesthetics, gastroenterology, and inflammation therapeutic areas.
- Company typePrivate
- Founded1997
- HeadquartersMünster, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Proinnovera does
Proinnovera is a German-based Contract Research Organization (CRO), headquartered in Münster, providing clinical research and consulting services to pharmaceutical and biotechnology clients. Founded in 1997 and operating with 51-100 employees, the firm specializes in clinical development across four therapeutic areas: dermatology, aesthetics, gastroenterology, and inflammation, with particular expertise in topical formulation development for dermatological and aesthetic applications. The business operates on a professional services model, executing clinical trials and delivering research services under negotiated B2B contracts with pharma and biotech companies on a project-by-project basis.
In October 2023, Proinnovera merged with Symbio and the Dow Group to form a unified entity initially branded Symbio Proinnovera. Following the integration, the combined organization rebranded to Symbio in September 2024, retaining the Dow Development Laboratory branding as a wholly-owned subsidiary. The current company claims a Global geographic reach and positions itself as a specialized mid-sized Global CRO differentiated by combined therapeutic expertise and topical formulation capabilities. CEO Alan Morgan leads the organization, which has migrated its email communications to the symbioresearch.com domain. Distribution relies on direct enterprise client engagement rather than traditional sales channels, with marketing presence across LinkedIn, X, and Facebook supplementing the firm's website and client communications.
The company has no disclosed funding rounds, no public revenue figures, and no parent company or private equity backing indicated in available data. The Dow Development Laboratory subsidiary is the only disclosed corporate structure element, retained as an acquired brand following the merger integration.
Proinnovera firmographics
Firmographics- Name
- Proinnovera
- Legal name
- Symbio Research
- Website
- https://proinnovera.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Proinnovera is a German-based Global CRO providing clinical research and topical formulation development services to pharmaceutical and biotech clients across dermatology, aesthetics, gastroenterology, and inflammation therapeutic areas.
- Ownership category
- akta.pro rank
Proinnovera industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where Proinnovera is headquartered
LocationHeadquarters
- HQ city
- Münster
- HQ country
- Germany
- HQ region
- Europe
Markets served
Proinnovera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Contract Research Services: Professional services revenue generated through conducting clinical trials and providing research services to pharmaceutical and biotech companies under contract arrangements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Proinnovera product offering
Product offeringCore offering
Proinnovera, now operating as part of Symbio following the 2023 merger with Symbio & Dow Group, is a Global Contract Research Organization (CRO) that provides consulting, planning, and implementation services for pharmaceutical product development. The company delivers clinical research services with specialized topical formulation development capabilities and focused therapeutic area expertise in dermatology, aesthetics, gastroenterology, and inflammation for pharmaceutical and biotech clients.
Product overview
Symbio (formerly Symbio Proinnovera) is a Global Contract Research Organization (CRO) providing clinical research services. The company offers a unified portfolio combining topical formulation development services with therapeutic expertise across four key areas: Dermatology, Aesthetics, Gastroenterology, and Inflammation. Services include specialized topical formulation development and access to Symbio's global research networks, all delivered as an integrated CRO offering to pharmaceutical and biotech clients.
Differentiator
Problem solved
Functional benefit
Products and services
- Topical Formulation Development Specialized development services for topical pharmaceutical formulations, supporting drug development in dermatology and aesthetics therapeutic areas. Targeted at pharmaceutical and biotech companies requiring topical drug product development expertise.
- Symbio's Networks Global network services connecting pharmaceutical and biotech clients with clinical trial capabilities and research infrastructure across multiple regions worldwide. Provides access to international research sites and trial execution resources.
- Dermatology Clinical Research Clinical research services for dermatological conditions and treatments, supporting pharmaceutical and biotech clients developing drugs for skin-related indications.
- Aesthetics Clinical Research Clinical research and development services for aesthetic medicine products, serving pharmaceutical and biotech clients developing aesthetic and cosmetic pharmaceutical products.
- Gastroenterology Clinical Research Clinical research services for gastrointestinal conditions and treatments, supporting pharmaceutical and biotech clients developing drugs for GI-related indications.
- Inflammation Clinical Research Clinical research and drug development services for inflammation-related conditions, serving pharmaceutical and biotech clients developing anti-inflammatory therapeutics.
Companies that use Proinnovera
Customer profileSegments6 records
Ideal customer profiles1 record
Proinnovera technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Proinnovera partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Dow GroupcoreDow Group merged with Symbio and Proinnovera GmbH to form the unified Symbio organization. The Dow Development Laboratory branding remains unchanged as part of the post-merger integration. This merger combined the expertise and capabilities of three organizations into a single Global CRO entity.
- Proinnovera GmbHcoreProinnovera GmbH merged with Symbio and Dow Group. The combined entity operated under the name Symbio Proinnovera before rebranding to simply Symbio in September 2024. The merger brought together complementary expertise in clinical research services.
Scale indicators1 record
Recent moves5 records
Expansion highlights3 records
Proinnovera competitors and assessment
Company assessmentBroad incumbents
- Fortrea (formerly Labcorp Drug Development): Global full-service CRO spin-out from Labcorp; competes across the same therapeutic areas and customer base that Symbio targets.
- Parexel International: Global full-service CRO covering all major therapeutic areas; sets the benchmark Symbio competes against when sponsors consolidate spend with a single large provider.
- ICON plc: One of the largest global CROs offering full-service clinical development across all therapeutic areas — represents the incumbent scale competitor for any CRO growing into broader mandates.
- IQVIA: World's largest CRO with global infrastructure, technology platforms, and analytics — the dominant broad incumbent that mid-tier specialty CROs like Symbio compete against for sponsor share.
- Charles River Laboratories: Large CRO/CDMO with significant clinical services business; broad incumbent playing in dermatology and inflammation — directly relevant therapeutic-area overlap with Symbio.
- Syneos Health: Large biopharma solutions and clinical development services provider; competes for outsourced clinical work from the same pharma/biotech customer base Symbio serves.
Direct peers
- Medpace: Mid-size, therapeutically-focused CRO with strong specialty-area expertise — the most directly comparable publicly-listed specialty CRO business model to Symbio's TA-driven positioning.
- Worldwide Clinical Trials: Mid-size CRO with concentrated therapeutic-area expertise in similar specialty categories; competes for the same kind of specialty biotech and mid-pharma clinical development work.
- Clinipace Worldwide: Smaller private CRO with a therapeutic-area-focused model, comparable in size and operating posture to Symbio's specialty mid-tier positioning.
Emerging players
- Frontage Laboratories: Mid-size CRO/CDMO with growing clinical and bioanalytical services; emerging specialty player of comparable scale whose expansion in dermatology-related work is a relevant adjacency to Symbio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Proinnovera social profiles
Digital presenceProinnovera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proinnovera leadership team
Management profileNumber of profiles
Profiles1 record
Proinnovera subsidiaries and ownership
Company hierarchySubsidiaries1 record
Proinnovera funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proinnovera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proinnovera
What does Proinnovera do?
Proinnovera, now operating as part of Symbio following the 2023 merger with Symbio & Dow Group, is a Global Contract Research Organization (CRO) that provides consulting, planning, and implementation services for pharmaceutical product development. The company delivers clinical research services with specialized topical formulation development capabilities and focused therapeutic area expertise in dermatology, aesthetics, gastroenterology, and inflammation for pharmaceutical and biotech clients.
Is Proinnovera a public or private company?
Proinnovera is a private company. It is classified as unknown and is currently operating.
When was Proinnovera founded?
Proinnovera was founded in 1997. It employs 51 to 100 people.
Where is Proinnovera based?
Proinnovera is headquartered in Münster, Germany, in the Europe region.
How does Proinnovera make money?
One revenue line is on record: contract Research Services.
Who are Proinnovera's main competitors?
Broad incumbents on record are Fortrea (formerly Labcorp Drug Development), Parexel International, ICON plc, IQVIA, Charles River Laboratories and Syneos Health. Direct peers are Medpace, Worldwide Clinical Trials and Clinipace Worldwide. Frontage Laboratories is listed as an emerging player.
Does Proinnovera have an API?
No public API is recorded for Proinnovera.
What industry is Proinnovera in?
Proinnovera's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 541714.